Last 12 months
Inside the activity.
1 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 25, 2022 Filed Apr 25, 2022 18:54 UTC |
Marango JotinCFO & Head of Corp. Dev.
|
GrantStock Option (Right to Buy) · Derivative | 397,199 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0000899243-22-015586 · doc4.xml · derivative · entry 1 Marango Jotin · CIK 0001777513 · CFO & Head of Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,199 Underlying: Common Stock · 397,199 shares Expires 2032-04-25 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on April 25, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 03, 2022 Filed Feb 4, 2022 18:12 UTC |
Manfredi MarkDirector · President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 238,900 | $0.00 Strike: $9.76 | $0.00 |
DisclosureSEC source: 0000899243-22-004884 · doc4.xml · derivative · entry 1 Manfredi Mark · CIK 0001848547 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,900 Underlying: Common Stock · 238,900 shares Expires 2032-02-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 18:14 UTC |
Zhang Xiaoyan MichelleChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $11.45 | $0.00 |
DisclosureSEC source: 0000899243-22-004887 · doc4.xml · derivative · entry 1 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 18:10 UTC |
Ecsedy JeffreyChief Development Officer
|
GrantStock Option (Right to Buy) · Derivative | 59,360 | $0.00 Strike: $11.45 | $0.00 |
DisclosureSEC source: 0000899243-22-004882 · doc4.xml · derivative · entry 1 Ecsedy Jeffrey · CIK 0001848533 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,360 Underlying: Common Stock · 59,360 shares Expires 2032-02-02 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 18:12 UTC |
Santillana Sergio L.Chief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 70,400 | $0.00 Strike: $11.45 | $0.00 |
DisclosureSEC source: 0000899243-22-004886 · doc4.xml · derivative · entry 1 Santillana Sergio L. · CIK 0001708767 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,400 Underlying: Common Stock · 70,400 shares Expires 2032-02-02 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 23:09 UTC |
Tessier MaudeChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $11.45 | $0.00 |
DisclosureSEC source: 0000899243-22-004878 · doc4.xml · derivative · entry 1 Tessier Maude · CIK 0001848534 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 21:34 UTC |
Wooster RichardDirector
|
GrantStock Option (Right to Buy) · Derivative | 29,200 | $0.00 Strike: $11.06 | $0.00 |
DisclosureSEC source: 0000899243-22-003237 · doc4.xml · derivative · entry 1 Wooster Richard · CIK 0001774790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,200 Underlying: Common Stock · 29,200 shares Expires 2032-01-21 F1 · derivative.exercise_date: This option will vest in equal installments on the first, second, and third anniversaries of the grant date. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:30 UTC |
Tessier MaudeChief Business Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,265 | $0.00 Strike: $4.51 | $0.00 |
DisclosureSEC source: 0000899243-22-002657 · doc4.xml · derivative · entry 6 Tessier Maude · CIK 0001848534 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,963 Underlying: Common Stock · 8,265 shares Expires 2029-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option vested and became exercisable on December 6, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:30 UTC |
Tessier MaudeChief Business Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 24,606 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0000899243-22-002657 · doc4.xml · derivative · entry 5 Tessier Maude · CIK 0001848534 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,186 Underlying: Common Stock · 24,606 shares Expires 2029-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 20, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:30 UTC |
Tessier MaudeChief Business Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 38,915 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0000899243-22-002657 · doc4.xml · derivative · entry 4 Tessier Maude · CIK 0001848534 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,560 Underlying: Common Stock · 38,915 shares Expires 2028-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of this option vested and became exercisable on July 16, 2019, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:30 UTC |
Tessier MaudeChief Business Officer
|
Exercise / conversionCommon Stock | 8,265 | $4.51 | $37,275.15 |
DisclosureSEC source: 0000899243-22-002657 · doc4.xml · nonDerivative · entry 3 Tessier Maude · CIK 0001848534 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:30 UTC |
Tessier MaudeChief Business Officer
|
Exercise / conversionCommon Stock | 24,606 | $4.15 | $102,114.90 |
DisclosureSEC source: 0000899243-22-002657 · doc4.xml · nonDerivative · entry 2 Tessier Maude · CIK 0001848534 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:30 UTC |
Tessier MaudeChief Business Officer
|
Exercise / conversionCommon Stock | 38,915 | $2.94 | $114,410.10 |
DisclosureSEC source: 0000899243-22-002657 · doc4.xml · nonDerivative · entry 1 Tessier Maude · CIK 0001848534 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 19:25 UTC |
Zhang Xiaoyan MichelleChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 964 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0000899243-22-001806 · doc4.xml · derivative · entry 6 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,473 Underlying: Common Stock · 964 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 19:25 UTC |
Zhang Xiaoyan MichelleChief Scientific Officer
|
SaleCommon Stock | 964 | $12.00 | $11,568.00 |
DisclosureSEC source: 0000899243-22-001806 · doc4.xml · nonDerivative · entry 4 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,475 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2021. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 19:25 UTC |
Zhang Xiaoyan MichelleChief Scientific Officer
|
Exercise / conversionCommon Stock | 964 | $2.15 | $2,068.94 |
DisclosureSEC source: 0000899243-22-001806 · doc4.xml · nonDerivative · entry 3 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 19:25 UTC |
Zhang Xiaoyan MichelleChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 36 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0000899243-22-001806 · doc4.xml · derivative · entry 5 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,437 Underlying: Common Stock · 36 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 19:25 UTC |
Zhang Xiaoyan MichelleChief Scientific Officer
|
SaleCommon Stock | 36 | $12.00 | $432.00 |
DisclosureSEC source: 0000899243-22-001806 · doc4.xml · nonDerivative · entry 2 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,475 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2021. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 19:25 UTC |
Zhang Xiaoyan MichelleChief Scientific Officer
|
Exercise / conversionCommon Stock | 36 | $2.15 | $77.26 |
DisclosureSEC source: 0000899243-22-001806 · doc4.xml · nonDerivative · entry 1 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 23:43 UTC |
FORMELA JEAN FRANCOISDirector
|
GrantStock Option (Right to Buy) · Derivative | 13,419 | $0.00 Strike: $14.92 | $0.00 |
DisclosureSEC source: 0000899243-21-049693 · doc4.xml · derivative · entry 1 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,419 Underlying: Common Stock · 13,419 shares Expires 2031-12-21 F1 · derivative.exercise_date: This option shall vest (1) 25% on December 21, 2022, and the remaining shall vest in equal monthly installments over the next 36 months. F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 18:46 UTC |
Koehler MariaDirector
|
GrantStock Option (Right to Buy) · Derivative | 13,419 | $0.00 Strike: $14.92 | $0.00 |
DisclosureSEC source: 0000899243-21-049696 · doc4.xml · derivative · entry 1 Koehler Maria · CIK 0001815378 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,419 Underlying: Common Stock · 13,419 shares Expires 2031-12-21 F1 · derivative.exercise_date: This option shall vest (1) 25% on December 21, 2022, and the remaining shall vest in equal monthly installments over the next 36 months. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 23:28 UTC |
Bonita David PDirector
|
GrantStock Option (Right to Buy) · Derivative | 13,419 | $0.00 Strike: $14.92 | $0.00 |
DisclosureSEC source: 0000899243-21-049677 · doc4.xml · derivative · entry 1 Bonita David P · CIK 0001572451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,419 Underlying: Common Stock · 13,419 shares Expires 2031-12-21 F1 · derivative.exercise_date: This option shall vest (1) 25% on December 21, 2022, and the remaining shall vest in equal monthly installments over the next 36 months. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 23:35 UTC |
Renaud Ronald C JRDirector
|
GrantStock Option (Right to Buy) · Derivative | 13,419 | $0.00 Strike: $14.92 | $0.00 |
DisclosureSEC source: 0000899243-21-049685 · doc4.xml · derivative · entry 1 Renaud Ronald C JR · CIK 0001354434 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,419 Underlying: Common Stock · 13,419 shares Expires 2031-12-21 F1 · derivative.exercise_date: This option shall vest (1) 25% on December 21, 2022, and the remaining shall vest in equal monthly installments over the next 36 months. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 23:43 UTC |
Stampacchia OtelloDirector
|
GrantStock Option (Right to Buy) · Derivative | 13,419 | $0.00 Strike: $14.92 | $0.00 |
DisclosureSEC source: 0000899243-21-049694 · doc4.xml · derivative · entry 1 Stampacchia Otello · CIK 0001361712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,419 Underlying: Common Stock · 13,419 shares Expires 2031-12-21 F1 · derivative.exercise_date: This option shall vest (1) 25% on December 21, 2022, and the remaining shall vest in equal monthly installments over the next 36 months. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 23:39 UTC |
Dukes Iain D.Director
|
GrantStock Option (Right to Buy) · Derivative | 23,419 | $0.00 Strike: $14.92 | $0.00 |
DisclosureSEC source: 0000899243-21-049690 · doc4.xml · derivative · entry 1 Dukes Iain D. · CIK 0001681955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,419 Underlying: Common Stock · 23,419 shares Expires 2031-12-21 F1 · derivative.exercise_date: This option shall vest (1) 25% on December 21, 2022, and the remaining shall vest in equal monthly installments over the next 36 months. Read SEC document |
| December 14, 2021 Filed Dec 15, 2021 01:29 UTC |
FORMELA JEAN FRANCOISDirector
|
SaleCommon Stock | 5,959 | $14.00 | $83,426.00 |
DisclosureSEC source: 0001209191-21-069645 · doc4.xml · nonDerivative · entry 4 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,241,935 F3 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of Associates XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 14, 2021 Filed Dec 15, 2021 01:27 UTC |
Atlas Venture Fund XI, L.P.10% owner
Atlas Venture Associates XI, L.P.10% owner
Atlas Venture Associates XI, LLC10% owner
|
SaleCommon Stock | 5,959 | $14.00 | $83,426.00 |
DisclosureSEC source: 0001209191-21-069644 · doc4.xml · nonDerivative · entry 4 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,241,935 F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 01:29 UTC |
FORMELA JEAN FRANCOISDirector
|
SaleCommon Stock | 8,330 | $14.64 | $121,951.20 |
DisclosureSEC source: 0001209191-21-069645 · doc4.xml · nonDerivative · entry 3 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,247,894 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.65 inclusive. F3 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of Associates XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 01:27 UTC |
Atlas Venture Fund XI, L.P.10% owner
Atlas Venture Associates XI, L.P.10% owner
Atlas Venture Associates XI, LLC10% owner
|
SaleCommon Stock | 8,330 | $14.64 | $121,951.20 |
DisclosureSEC source: 0001209191-21-069644 · doc4.xml · nonDerivative · entry 3 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,247,894 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.65 inclusive. F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 01:29 UTC |
FORMELA JEAN FRANCOISDirector
|
SaleCommon Stock | 11,989 | $15.03 | $180,194.67 |
DisclosureSEC source: 0001209191-21-069645 · doc4.xml · nonDerivative · entry 2 FORMELA JEAN FRANCOIS · CIK 0001030575 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,256,224 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.55 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4). F3 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of Associates XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 20:48 UTC |
Zhang Xiaoyan MichelleChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0000899243-21-048230 · doc4.xml · derivative · entry 3 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,473 Underlying: Common Stock · 1,000 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 20:48 UTC |
Zhang Xiaoyan MichelleChief Scientific Officer
|
SaleCommon Stock | 1,000 | $14.76 | $14,759.90 |
DisclosureSEC source: 0000899243-21-048230 · doc4.xml · nonDerivative · entry 2 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,475 Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 20:48 UTC |
Zhang Xiaoyan MichelleChief Scientific Officer
|
Exercise / conversionCommon Stock | 1,000 | $2.15 | $2,146.20 |
DisclosureSEC source: 0000899243-21-048230 · doc4.xml · nonDerivative · entry 1 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 01:27 UTC |
Atlas Venture Fund XI, L.P.10% owner
Atlas Venture Associates XI, L.P.10% owner
Atlas Venture Associates XI, LLC10% owner
|
SaleCommon Stock | 11,989 | $15.03 | $180,194.67 |
DisclosureSEC source: 0001209191-21-069644 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,256,224 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.55 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4). F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 21:01 UTC |
Zhang Xiaoyan MichelleChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 176,699 | $0.00 Strike: $13.75 | $0.00 |
DisclosureSEC source: 0000899243-21-045918 · doc4.xml · derivative · entry 1 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,699 Underlying: Common Stock · 176,699 shares Expires 2031-11-21 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 22, 2022, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| April 15, 2021 Filed Apr 15, 2021 18:55 UTC |
Koehler MariaDirector
|
GrantStock Option (Right to Buy) · Derivative | 26,838 | $0.00 Strike: $18.45 | $0.00 |
DisclosureSEC source: 0000899243-21-016001 · doc4.xml · derivative · entry 1 Koehler Maria · CIK 0001815378 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 Underlying: Common Stock · 26,838 shares Expires 2031-04-15 F1 · derivative.exercise_date: This option shall vest and become exercisable in 36 equal monthly installments beginning on April 15, 2021. Read SEC document |
| April 15, 2021 Filed May 3, 2021 19:05 UTC Amendment |
Koehler MariaDirector
|
GrantStock Option (Right to Buy) · Derivative | 26,838 | $0.00 Strike: $18.45 | $0.00 |
DisclosureSEC source: 0000899243-21-017841 · doc4a.xml · derivative · entry 1 Koehler Maria · CIK 0001815378 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 Underlying: Common Stock · 26,838 shares Expires 2031-04-15 F1 · derivative.exercise_date: This option will vest in equal installments on the first, second, and third anniversaries of the grant date. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:13 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP VI LLCDirector
OrbiMed Genesis GP LLCDirector
|
ConversionSeries B Preferred Stock · Derivative | 68,978 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014386 · doc4.xml · derivative · entry 16 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP VI LLC · CIK 0001682115 · Director OrbiMed Genesis GP LLC · CIK 0001808744 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See foonotes Disclosed balance after: 0 Underlying: Common Stock · 68,978 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3 · ownership.nature: The securities are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis. F8 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:13 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP VI LLCDirector
OrbiMed Genesis GP LLCDirector
|
ConversionSeries B Preferred Stock · Derivative | 130,924 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014386 · doc4.xml · derivative · entry 15 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP VI LLC · CIK 0001682115 · Director OrbiMed Genesis GP LLC · CIK 0001808744 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See foonotes Disclosed balance after: 0 Underlying: Non-Voting Common Stock · 130,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F7 · derivative.exercise_price: Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F7 · price: Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F7 · derivative.exercise_date: Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F7 · derivative.expiration_date: Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F3 · ownership.nature: The securities are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis. F8 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:13 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP VI LLCDirector
OrbiMed Genesis GP LLCDirector
|
ConversionSeries B Preferred Stock · Derivative | 328,907 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014386 · doc4.xml · derivative · entry 14 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP VI LLC · CIK 0001682115 · Director OrbiMed Genesis GP LLC · CIK 0001808744 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See foonotes Disclosed balance after: 0 Underlying: Common Stock · 328,907 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationship, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI. F8 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:13 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP VI LLCDirector
OrbiMed Genesis GP LLCDirector
|
ConversionSeries B Preferred Stock · Derivative | 920,484 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014386 · doc4.xml · derivative · entry 13 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP VI LLC · CIK 0001682115 · Director OrbiMed Genesis GP LLC · CIK 0001808744 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See foonotes Disclosed balance after: 0 Underlying: Non-Voting Common Stock · 920,484 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F7 · derivative.exercise_price: Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F7 · price: Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F7 · derivative.exercise_date: Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F7 · derivative.expiration_date: Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F2 · ownership.nature: The securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationship, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI. F8 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:13 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP VI LLCDirector
OrbiMed Genesis GP LLCDirector
|
ConversionSeries A-1 Preferred Stock · Derivative | 806,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014386 · doc4.xml · derivative · entry 12 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP VI LLC · CIK 0001682115 · Director OrbiMed Genesis GP LLC · CIK 0001808744 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See foonotes Disclosed balance after: 0 Underlying: Common Stock · 806,752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationship, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI. F8 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:13 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP VI LLCDirector
OrbiMed Genesis GP LLCDirector
|
ConversionSeries A-1 Preferred Stock · Derivative | 2,257,785 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014386 · doc4.xml · derivative · entry 11 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP VI LLC · CIK 0001682115 · Director OrbiMed Genesis GP LLC · CIK 0001808744 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See foonotes Disclosed balance after: 0 Underlying: Non-Voting Common Stock · 2,257,785 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F7 · derivative.exercise_price: Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F7 · price: Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F7 · derivative.exercise_date: Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F7 · derivative.expiration_date: Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F2 · ownership.nature: The securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationship, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI. F8 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:13 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP VI LLCDirector
OrbiMed Genesis GP LLCDirector
|
ConversionSeries A Preferred Stock · Derivative | 680,766 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014386 · doc4.xml · derivative · entry 10 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP VI LLC · CIK 0001682115 · Director OrbiMed Genesis GP LLC · CIK 0001808744 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See foonotes Disclosed balance after: 0 Underlying: Common Stock · 680,766 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationship, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI. F8 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:13 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP VI LLCDirector
OrbiMed Genesis GP LLCDirector
|
ConversionSeries A Preferred Stock · Derivative | 1,905,201 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014386 · doc4.xml · derivative · entry 9 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP VI LLC · CIK 0001682115 · Director OrbiMed Genesis GP LLC · CIK 0001808744 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See foonotes Disclosed balance after: 0 Underlying: Non-Voting Common Stock · 1,905,201 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F7 · derivative.exercise_price: Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F7 · price: Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F7 · derivative.exercise_date: Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F7 · derivative.expiration_date: Each share of Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Non-Voting Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F2 · ownership.nature: The securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationship, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI. F8 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:13 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP VI LLCDirector
OrbiMed Genesis GP LLCDirector
|
ConversionNon-Voting Common Stock | 130,924 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014386 · doc4.xml · nonDerivative · entry 6 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP VI LLC · CIK 0001682115 · Director OrbiMed Genesis GP LLC · CIK 0001808744 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 130,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3 · ownership.nature: The securities are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis. F8 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:13 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP VI LLCDirector
OrbiMed Genesis GP LLCDirector
|
ConversionNon-Voting Common Stock | 5,083,470 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014386 · doc4.xml · nonDerivative · entry 5 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP VI LLC · CIK 0001682115 · Director OrbiMed Genesis GP LLC · CIK 0001808744 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 5,083,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationship, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI. F8 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:13 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP VI LLCDirector
OrbiMed Genesis GP LLCDirector
|
PurchaseCommon Stock | 48,400 | $16.00 | $774,400.00 |
DisclosureSEC source: 0000899243-21-014386 · doc4.xml · nonDerivative · entry 4 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP VI LLC · CIK 0001682115 · Director OrbiMed Genesis GP LLC · CIK 0001808744 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 117,378 F3 · ownership.nature: The securities are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis. F8 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:13 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP VI LLCDirector
OrbiMed Genesis GP LLCDirector
|
PurchaseCommon Stock | 375,000 | $16.00 | $6,000,000.00 |
DisclosureSEC source: 0000899243-21-014386 · doc4.xml · nonDerivative · entry 3 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP VI LLC · CIK 0001682115 · Director OrbiMed Genesis GP LLC · CIK 0001808744 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 2,191,425 F2 · ownership.nature: The securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationship, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI. F8 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:13 UTC |
ORBIMED ADVISORS LLCDirector
OrbiMed Capital GP VI LLCDirector
OrbiMed Genesis GP LLCDirector
|
ConversionCommon Stock | 68,978 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014386 · doc4.xml · nonDerivative · entry 2 ORBIMED ADVISORS LLC · CIK 0001055951 · Director OrbiMed Capital GP VI LLC · CIK 0001682115 · Director OrbiMed Genesis GP LLC · CIK 0001808744 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 68,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. These shares of Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3 · ownership.nature: The securities are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis. F8 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.